Person
Dr. Lange contributes her expertise on chronic HIV infection to provide cellular models of clinical relevance to test newly developed therapeutic strategies developed in HOPE.
Leibniz Institute of Virology and University Medical Center Hamburg-Eppendorf
Dr. Murthy’s lab will be developing innovative ways for delivering genome editing enzymes to T cells.
The University of California at Berkeley and the Innovative Genomics Institute
Dr. Mwesigwa is the site principal investigator for the MUWRP study that collects biospecimens for the characterization of HIV reservoirs in different body compartments and oversees all procedures related to recruitment, community outreach, participant enrollment, and follow up for the HOPE study.
Makerere University Walter Reed Project
Dr. Nath will work on understanding the role of HIV in the brain and the effects of ‘block-lock-excise’ strategies on HIV in the brain.
Dr. Ndhlovu research program is dedicated to confronting the challenges of HIV and aging using immuno-epigenetic approaches to resolve molecular mechanisms of HIV age related complications and viral persistence.
Dr. Nixon’s group will be working closely with Cedric Feschotte and his team to learn how HERVs may give clues to locking HIV.
Dr. Ott is the Program Director for HOPE. Her work focuses on the role of reversible protein acetylation in HIV transcription and identifying molecular mechanisms controlling viral latency.
Dr. Roan will investigate the mechanisms underlying transcriptional silencing of the HIV provirus, and the host features that prevent “block and lock” after a variety of therapeutic interventions.
Dr. Sameshima will work on developing cure curriculum and education through community arts integrated research.
Dr. Valente’s research focuses on mechanisms that regulate HIV-1 latency in CD4+T memory T cells and development of antiviral molecules that suppress the latent reservoir.